BSEOthers10 Aug 2026 · 10 Aug 2026, 04:10 pm
Please find attached outcome of board meeting
Mankind Pharma Ltd · 543904
✦ AI SummaryMgmt Change
Mankind Pharma Ltd has announced the appointment of Mr. Anish Vanraj Bafna as an Additional Director, designated as a Non-Executive Independent Director, with effect from August 10, 2026. The appointment is subject to approval by the members of the Company. Mr. Bafna has over 30 years of experience in the healthcare and medical devices sector, with significant experience in managing global healthcare businesses and operations across multiple geographies.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment6/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Mankind Pharma Ltd - 543904 - Board Meeting Outcome for For Appointment Of An Additional Director Designated As Non-Executive Independent Director
Attachments (1)
📄pdf
Download →
3f535086-4374-40d4-9180-ce436bb5a74b.pdf
View document text
August 10, 2026
BSE Limited National Stock Exchange of India Limited
P J Towers, Exchange Plaza, C-1, Block G,
Dalal Street, Bandra Kurla Complex,
Mumbai – 400 001 Bandra (E), Mumbai – 400 051
Scrip Code: 543904 Symbol: MANKIND
Dear Sir/ Madam,
Subject: Outcome of Board Meeting
Ref.: Regulation 30 & 51 of the Securities and Exchange Board of India (Listing Obligations
and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)
Pursuant to Regulation 30 & 51 read with Part A of Schedule III and other applicable provisions of the
Listing Regulations, we wish to inform you that the Board of Directors of the Company, at its meeting
held today i.e. Monday, August 10, 2026, has inter alia considered and approved:
i. the appointment of Mr. Anish Vanraj Bafna (DIN: 02925792) as an Additional Director, designated
as a Non-Executive Independent Director of the Company, with effect from August 10, 2026, based
on the recommendation of the Nomination and Remuneration Committee.
ii. the Postal Ballot Notice for seeking approval of the members of the Company for the appointment
of Mr. Anish Vanraj Bafna, as a Non-Executive Independent Director, for a term of 5 (five)
consecutive years. The Postal Ballot Notice will be circulated to the members of the Company in
due course.
Further, declaration pursuant to BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018, and
NSE Circular No. NSE/ CML/2018/24 dated June 20, 2018 has been obtained that Mr. Anish Vanraj
Bafna is not debarred from holding office of a Director by virtue of any order passed by the Securities
and Exchange Board of India (“SEBI”) or any other such authority.
The detailed disclosure required pursuant to the applicable provisions of the Listing Regulations and
SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated January 30, 2026 (“SEBI Master
Circular”) is enclosed as Annexure I.
The Board Meeting commenced at 03:30 p.m. (IST) and concluded at 03:45 p.m. (IST).
You are requested to kindly take the above information on your records.
Thanking You,
Yours Faithfully,
For Mankind Pharma Limited
Hitesh Kumar Jain
Company Secretary &
Compliance Officer
Encl.: A/a
Annexure-I
The detailed disclosure required pursuant to the applicable provisions of the Listing Regulations and SEBI
Master Circular:
Sr. Particulars Details
1. Name Mr. Anish Vanraj Bafna (DIN: 02925792)
2. Reason for change viz. appointment, Appointed as an Additional Director in the category of Non-Executive,
re-appointment, resignation, Independent Director.
removal, death or otherwise
3. Date of appointment/re- Appointment for a term of 5 (five) consecutive years effective from
appointment/cessation (as August 10, 2026, subject to approval of members of the Company.
applicable) & term of
appointment/re-appointment;
4. Brief profile (in case of Mr. Anish Vanraj Bafna has over 30 years of experience in the
appointment) healthcare and medical devices sector, with significant experience in
managing global healthcare businesses and operations across multiple
geographies.
Mr. Bafna previously served as the Chief Executive Officer and
Managing Director of Healthium Medtech Limited (“Healthium”) for
over eight years, where he was instrumental in driving the company's
growth, global expansion and transformation. He is currently serving
as the Non-Executive Chairman of Healthium.
Prior to his association with Healthium, Mr. Bafna served as President
– Japan at Baxter International. He had also served as Regional Head –
Emerging Asia at Baxter International, Singapore, where he was
responsible for overseeing operations across India and Southeast Asia.
Over the course of his career, Mr. Bafna has worked across Vietnam,
Indonesia, Malaysia, Singapore, Japan and India, gaining extensive
international experience in healthcare business management, strategy
development and operational excellence.
Mr. Bafna holds a Bachelor’s Degree in Science (Chemistry) from St.
Xavier’s, Ahmedabad, and a Post Graduate Diploma in Management
(PGDM) from IMDR, Pune.
5. Disclosure of relationships between Mr. Bafna is not related to any Promoter, Director or Key Managerial
directors Personnel of the Company and does not have any inter se relationship
with any of the existing Director of the Company. He satisfies the
criteria of Independence prescribed under the provisions of the
Companies Act, 2013 and Listing Regulations.